31,831 Shares in Caribou Biosciences, Inc. (NASDAQ:CRBU) Purchased by Point72 Asia Singapore Pte. Ltd.

Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 31,831 shares of the company’s stock, valued at approximately $52,000.

A number of other hedge funds have also recently added to or reduced their stakes in CRBU. Westwood Holdings Group Inc. grew its position in Caribou Biosciences by 81.9% in the fourth quarter. Westwood Holdings Group Inc. now owns 277,205 shares of the company’s stock valued at $1,588,000 after acquiring an additional 124,769 shares during the last quarter. Pale Fire Capital SE bought a new stake in shares of Caribou Biosciences in the fourth quarter worth $162,000. Avidity Partners Management LP increased its holdings in Caribou Biosciences by 5.1% in the fourth quarter. Avidity Partners Management LP now owns 6,360,212 shares of the company’s stock valued at $36,444,000 after purchasing an additional 310,000 shares during the period. Wellington Management Group LLP increased its holdings in Caribou Biosciences by 57.7% in the fourth quarter. Wellington Management Group LLP now owns 314,080 shares of the company’s stock valued at $1,800,000 after purchasing an additional 114,975 shares during the period. Finally, Green Alpha Advisors LLC raised its position in Caribou Biosciences by 5.0% during the 1st quarter. Green Alpha Advisors LLC now owns 83,521 shares of the company’s stock worth $429,000 after purchasing an additional 3,957 shares during the last quarter. Institutional investors own 77.51% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on CRBU shares. Evercore ISI lowered Caribou Biosciences from an “outperform” rating to an “inline” rating and dropped their price target for the company from $13.00 to $3.00 in a research note on Monday, June 3rd. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price target on shares of Caribou Biosciences in a research note on Tuesday, September 3rd. Finally, Royal Bank of Canada restated an “outperform” rating and set a $14.00 price objective on shares of Caribou Biosciences in a report on Wednesday, August 7th. One investment analyst has rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $11.25.

Caribou Biosciences Price Performance

Shares of NASDAQ:CRBU opened at $1.96 on Tuesday. Caribou Biosciences, Inc. has a one year low of $1.50 and a one year high of $8.33. The firm has a market capitalization of $177.02 million, a price-to-earnings ratio of -1.35 and a beta of 2.29. The company’s fifty day moving average price is $2.07 and its 200-day moving average price is $2.81.

Caribou Biosciences (NASDAQ:CRBU) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.04. Caribou Biosciences had a negative return on equity of 34.76% and a negative net margin of 372.78%. The business had revenue of $3.46 million for the quarter, compared to the consensus estimate of $3.31 million. As a group, equities research analysts expect that Caribou Biosciences, Inc. will post -1.76 EPS for the current year.

Caribou Biosciences Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.